The database of the Danish Renal Cancer Group

Astrid Christine Petersen; Mette Søgaard; Frank Mehnert; Erik Højkjær Larsen; Frede Donskov; Nessn H Azawi; Bjarne Kromann-Andersen

doi:10.2147/CLEP.S106042

The database of the Danish Renal Cancer Group

Astrid Christine Petersen, Mette Søgaard, Frank Mehnert, Erik Højkjær Larsen, Frede Donskov, Nessn H Azawi, Bjarne Kromann-Andersen

Research output: Contribution to journal › Review article › peer-review

8 Citations (Scopus)

Abstract

AIM OF THE DATABASE: The main purpose of the database of the Danish Renal Cancer Group (DaRenCaData) is to improve the quality of renal cancer treatment in Denmark and secondarily to conduct observational research.

STUDY POPULATION: DaRenCaData includes all Danish patients with a first-time diagnosis of renal cancer in the Danish National Pathology Registry since August 1, 2010.

MAIN VARIABLES: DaRenCaData holds data on demographic characteristics, treatments, and pathology collected through linkage to central registries and online registration of a few clinical key variables. Eight quality indicators have been selected for monitoring treatment quality and outcome after renal cancer.

DESCRIPTIVE DATA: The incidence of renal cancer in Denmark has increased from 12.7 per 100,000 population-years in 2010-2011 to 15.9 per 100,000 population-years in 2014-2015. A total of 3,977 Danish patients with renal cancer have been enrolled in the database in the period August 1, 2010-July 31, 2015. The completeness of data registration has increased substantially since the first years of the database. A tendency toward smaller and less advanced tumors, less invasive surgery, and a shorter hospital stay was observed, while the postoperative morbidity and mortality remained stable. Concurrently, the 1-year survival has improved and was 84.1% in 2014-2015.

CONCLUSION: DaRenCaData provides valuable information on quality of and outcome after renal cancer treatment. Efforts to improve collection and registration of data are ongoing.

Original language	English
Journal	Clinical Epidemiology
Volume	8
Pages (from-to)	725-729
Number of pages	5
ISSN	1179-1349
DOIs	https://doi.org/10.2147/CLEP.S106042
Publication status	Published - 2016

Access to Document

10.2147/CLEP.S106042Licence: CC BY-NC 3.0

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5098506/pdf/clep-8-725.pdfLicence: CC BY-NC 3.0

AUB Link

Search for the material in Aalborg University Library's search engine

Cite this

@article{ebc2433acc1041b0a9c6daf5e30e560d,

title = "The database of the Danish Renal Cancer Group",

abstract = "AIM OF THE DATABASE: The main purpose of the database of the Danish Renal Cancer Group (DaRenCaData) is to improve the quality of renal cancer treatment in Denmark and secondarily to conduct observational research.STUDY POPULATION: DaRenCaData includes all Danish patients with a first-time diagnosis of renal cancer in the Danish National Pathology Registry since August 1, 2010.MAIN VARIABLES: DaRenCaData holds data on demographic characteristics, treatments, and pathology collected through linkage to central registries and online registration of a few clinical key variables. Eight quality indicators have been selected for monitoring treatment quality and outcome after renal cancer.DESCRIPTIVE DATA: The incidence of renal cancer in Denmark has increased from 12.7 per 100,000 population-years in 2010-2011 to 15.9 per 100,000 population-years in 2014-2015. A total of 3,977 Danish patients with renal cancer have been enrolled in the database in the period August 1, 2010-July 31, 2015. The completeness of data registration has increased substantially since the first years of the database. A tendency toward smaller and less advanced tumors, less invasive surgery, and a shorter hospital stay was observed, while the postoperative morbidity and mortality remained stable. Concurrently, the 1-year survival has improved and was 84.1% in 2014-2015.CONCLUSION: DaRenCaData provides valuable information on quality of and outcome after renal cancer treatment. Efforts to improve collection and registration of data are ongoing.",

author = "Petersen, {Astrid Christine} and Mette S{\o}gaard and Frank Mehnert and Larsen, {Erik H{\o}jkj{\ae}r} and Frede Donskov and Azawi, {Nessn H} and Bjarne Kromann-Andersen",

year = "2016",

doi = "10.2147/CLEP.S106042",

language = "English",

volume = "8",

pages = "725--729",

journal = "Clinical Epidemiology",

issn = "1179-1349",

publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - The database of the Danish Renal Cancer Group

AU - Petersen, Astrid Christine

AU - Søgaard, Mette

AU - Mehnert, Frank

AU - Larsen, Erik Højkjær

AU - Donskov, Frede

AU - Azawi, Nessn H

AU - Kromann-Andersen, Bjarne

PY - 2016

Y1 - 2016

N2 - AIM OF THE DATABASE: The main purpose of the database of the Danish Renal Cancer Group (DaRenCaData) is to improve the quality of renal cancer treatment in Denmark and secondarily to conduct observational research.STUDY POPULATION: DaRenCaData includes all Danish patients with a first-time diagnosis of renal cancer in the Danish National Pathology Registry since August 1, 2010.MAIN VARIABLES: DaRenCaData holds data on demographic characteristics, treatments, and pathology collected through linkage to central registries and online registration of a few clinical key variables. Eight quality indicators have been selected for monitoring treatment quality and outcome after renal cancer.DESCRIPTIVE DATA: The incidence of renal cancer in Denmark has increased from 12.7 per 100,000 population-years in 2010-2011 to 15.9 per 100,000 population-years in 2014-2015. A total of 3,977 Danish patients with renal cancer have been enrolled in the database in the period August 1, 2010-July 31, 2015. The completeness of data registration has increased substantially since the first years of the database. A tendency toward smaller and less advanced tumors, less invasive surgery, and a shorter hospital stay was observed, while the postoperative morbidity and mortality remained stable. Concurrently, the 1-year survival has improved and was 84.1% in 2014-2015.CONCLUSION: DaRenCaData provides valuable information on quality of and outcome after renal cancer treatment. Efforts to improve collection and registration of data are ongoing.

AB - AIM OF THE DATABASE: The main purpose of the database of the Danish Renal Cancer Group (DaRenCaData) is to improve the quality of renal cancer treatment in Denmark and secondarily to conduct observational research.STUDY POPULATION: DaRenCaData includes all Danish patients with a first-time diagnosis of renal cancer in the Danish National Pathology Registry since August 1, 2010.MAIN VARIABLES: DaRenCaData holds data on demographic characteristics, treatments, and pathology collected through linkage to central registries and online registration of a few clinical key variables. Eight quality indicators have been selected for monitoring treatment quality and outcome after renal cancer.DESCRIPTIVE DATA: The incidence of renal cancer in Denmark has increased from 12.7 per 100,000 population-years in 2010-2011 to 15.9 per 100,000 population-years in 2014-2015. A total of 3,977 Danish patients with renal cancer have been enrolled in the database in the period August 1, 2010-July 31, 2015. The completeness of data registration has increased substantially since the first years of the database. A tendency toward smaller and less advanced tumors, less invasive surgery, and a shorter hospital stay was observed, while the postoperative morbidity and mortality remained stable. Concurrently, the 1-year survival has improved and was 84.1% in 2014-2015.CONCLUSION: DaRenCaData provides valuable information on quality of and outcome after renal cancer treatment. Efforts to improve collection and registration of data are ongoing.

U2 - 10.2147/CLEP.S106042

DO - 10.2147/CLEP.S106042

M3 - Review article

C2 - 27843350

SN - 1179-1349

VL - 8

SP - 725

EP - 729

JO - Clinical Epidemiology

JF - Clinical Epidemiology

ER -

The database of the Danish Renal Cancer Group

Abstract

Access to Document

AUB Link

Fingerprint

Cite this